Close Menu

This article has been updated from a previous version to include a statement provided by Epigenomics.

NEW YORK (GenomeWeb) – BioChain said today that it is considering legal action against Epigenomics for allegedly violating the terms of a licensing contract related to Chinese distribution rights to Epigenomics' Septin9 biomarker and Epi proColon colorectal cancer blood test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.